Professor Helena Erlandsson Harris ny föreståndare på CMM
CMM stiftelsens styrelse har utnämnt professor Helena Erlandsson Harris till ny föreståndare för Centrum för Molekylär Medicin. Styrelsens beslut var enhälligt och godkänt av Karolinska Universitetssjukhuset och Karolinska Universitetet. Tjänsten tillträds från och med den 15:e augusti 2017.
Se nedan för en intervju på engelska med tillträdande föreståndaren.
Meet the new Director
Helena, you have just been appointed to be the next director of CMM, starting the 15th of August. Congratulations!
Thank you, I am honoured to have been given this trust by the CMM board and I am excited by the challenges it will entail. I feel well prepared for the task after my years as vice-director and I will work hard to both preserve the good features of CMM and also to continue to develop CMM into an even better research environment.
I would also like to thank all CMMers that have voiced their support and congratulated me since the announcement last week.
What does it really entail to be the CMM director?
For me, being the CMM director means I have the responsibility to make CMM an exemplary environment in which excellent research is performed in a supportive and inclusive atmosphere. As the director I will have the executive task to realise the long-term strategy of the CMM foundation and to ensure that we have the best possible intellectual environment and infrastructure. Being director does not mean that I am the head of research at CMM as this task is best performed by each individual PI, but I will work with the over-arching strategy for research performed within the CMM environment.
How will you do this?
This will include both external and internal activities. With all the current events in our surroundings it is important to have an ongoing dialogue with both KI and Karolinska about research environments per se and specifically the interactions between the different milieus. I want CMM to be an active partner in strategy discussions with major stakeholders in medical research, and we also need to reach out to representatives in healthcare to develop strategies for how we ensure that patient samples will continue to be readily available for research in the future. These issues are of fundamental importance for the translational research performed within CMM.
Internally, I want to increase interactions between researchers and to establish a means to make better use of all the competence and experience within CMM. We have so many skilled and knowledgeable scientists within CMM and we have so much to learn from each other. Complementing this already existing and stable resource with recruitments of new groups will expand our research possibilities and make us even better prepared for the future.
This is of course nothing that I can accomplish alone and I will need the help and input from all CMMers.
What is on your agenda for the spring?
Firstly, to continue the preparations for relocation of CMM groups both within CMM and at U2. Secondly, to ensure that interactions between CMM groups at the two sites are facilitated and effective. I will appoint 1 or 2 vice-directors that will work closely together with me as soon as the group leaders have elected a new steering group.
Importantly, I want to have many interactions with CMM:ers on a personal basis, having informal discussions about CMM and the future. Everyone is welcome to come by my room for a chat and I look forward to start visiting groups at both L8 and U2. Of course I will continue to contribute to CMMs research together with my group and collaborators.